Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?
Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, prote...
Gespeichert in:
| Veröffentlicht in: | Current HIV/AIDS reports 2013-06, Vol.10 (2), p.142-151 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 151 |
|---|---|
| container_issue | 2 |
| container_start_page | 142 |
| container_title | Current HIV/AIDS reports |
| container_volume | 10 |
| creator | Baeten, Jared M. Grant, Robert |
| description | Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered – including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve on this effective technology. |
| doi_str_mv | 10.1007/s11904-013-0157-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3644362</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1348503763</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-3c981ace9ce1600b29524b9d41a8a8ed2bd63d544c933af148405a5b41753fe03</originalsourceid><addsrcrecordid>eNp9UctOwzAQtBCIQuEDuCAfuQTs2E5iDqCqPFpRCQ4tPVpO4rSpWrvYSRE3foPf40twlbaCC4fVrjyz49EOAGcYXWKE4iuHMUc0QJj4YnHA98ARZjQJCIuj_d0cJS1w7NwMIUI5jQ5BK1wPcRwegeHIKWgK2NFVaVVlzaq0cu5gYSzs9V_hi1Ur5TGjr-F4Kit4Z-BYwSdt3qHU-fZNf39-VVvg9gQcFF5EnW56G4we7ofdXjB4fux3O4MgozSsApLxBMtM8UzhCKE05CykKc8plolMVB6meURyRmnGCZEFpglFTLKU4piRQiHSBjeN7rJOFyrPvFFvXixtuZD2QxhZir-ILqdiYlaCRJSSKPQCFxsBa95q5SqxKF2m5nOplamdwIQmDJE4Ip6KG2pmjXNWFbtvMBLrNESThvBpiHUagvud89_-dhvb83tC2BCch_REWTEztdX-Zv-o_gASfpU-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1348503763</pqid></control><display><type>article</type><title>Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Baeten, Jared M. ; Grant, Robert</creator><creatorcontrib>Baeten, Jared M. ; Grant, Robert</creatorcontrib><description>Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered – including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve on this effective technology.</description><identifier>ISSN: 1548-3568</identifier><identifier>EISSN: 1548-3576</identifier><identifier>DOI: 10.1007/s11904-013-0157-9</identifier><identifier>PMID: 23494772</identifier><language>eng</language><publisher>New York: Current Science Inc</publisher><subject>Adenine - analogs & derivatives ; Adenine - therapeutic use ; Administration, Oral ; Administration, Topical ; Anti-HIV Agents - therapeutic use ; Chemoprevention ; Female ; HIV Infections - drug therapy ; HIV Infections - prevention & control ; Humans ; Male ; Medication Adherence - statistics & numerical data ; Medicine ; Medicine & Public Health ; Organophosphonates - therapeutic use ; Randomized Controlled Trials as Topic ; Risk Reduction Behavior ; Section Editor ; Sexual Behavior - statistics & numerical data ; Tenofovir ; The Global Epidemic (Q Abdool Karim</subject><ispartof>Current HIV/AIDS reports, 2013-06, Vol.10 (2), p.142-151</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-3c981ace9ce1600b29524b9d41a8a8ed2bd63d544c933af148405a5b41753fe03</citedby><cites>FETCH-LOGICAL-c442t-3c981ace9ce1600b29524b9d41a8a8ed2bd63d544c933af148405a5b41753fe03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11904-013-0157-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11904-013-0157-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,315,781,785,886,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23494772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baeten, Jared M.</creatorcontrib><creatorcontrib>Grant, Robert</creatorcontrib><title>Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?</title><title>Current HIV/AIDS reports</title><addtitle>Curr HIV/AIDS Rep</addtitle><addtitle>Curr HIV/AIDS Rep</addtitle><description>Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered – including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve on this effective technology.</description><subject>Adenine - analogs & derivatives</subject><subject>Adenine - therapeutic use</subject><subject>Administration, Oral</subject><subject>Administration, Topical</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Chemoprevention</subject><subject>Female</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - prevention & control</subject><subject>Humans</subject><subject>Male</subject><subject>Medication Adherence - statistics & numerical data</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Organophosphonates - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Reduction Behavior</subject><subject>Section Editor</subject><subject>Sexual Behavior - statistics & numerical data</subject><subject>Tenofovir</subject><subject>The Global Epidemic (Q Abdool Karim</subject><issn>1548-3568</issn><issn>1548-3576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctOwzAQtBCIQuEDuCAfuQTs2E5iDqCqPFpRCQ4tPVpO4rSpWrvYSRE3foPf40twlbaCC4fVrjyz49EOAGcYXWKE4iuHMUc0QJj4YnHA98ARZjQJCIuj_d0cJS1w7NwMIUI5jQ5BK1wPcRwegeHIKWgK2NFVaVVlzaq0cu5gYSzs9V_hi1Ur5TGjr-F4Kit4Z-BYwSdt3qHU-fZNf39-VVvg9gQcFF5EnW56G4we7ofdXjB4fux3O4MgozSsApLxBMtM8UzhCKE05CykKc8plolMVB6meURyRmnGCZEFpglFTLKU4piRQiHSBjeN7rJOFyrPvFFvXixtuZD2QxhZir-ILqdiYlaCRJSSKPQCFxsBa95q5SqxKF2m5nOplamdwIQmDJE4Ip6KG2pmjXNWFbtvMBLrNESThvBpiHUagvud89_-dhvb83tC2BCch_REWTEztdX-Zv-o_gASfpU-</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Baeten, Jared M.</creator><creator>Grant, Robert</creator><general>Current Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130601</creationdate><title>Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?</title><author>Baeten, Jared M. ; Grant, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-3c981ace9ce1600b29524b9d41a8a8ed2bd63d544c933af148405a5b41753fe03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Adenine - therapeutic use</topic><topic>Administration, Oral</topic><topic>Administration, Topical</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Chemoprevention</topic><topic>Female</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - prevention & control</topic><topic>Humans</topic><topic>Male</topic><topic>Medication Adherence - statistics & numerical data</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Organophosphonates - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Reduction Behavior</topic><topic>Section Editor</topic><topic>Sexual Behavior - statistics & numerical data</topic><topic>Tenofovir</topic><topic>The Global Epidemic (Q Abdool Karim</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baeten, Jared M.</creatorcontrib><creatorcontrib>Grant, Robert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current HIV/AIDS reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baeten, Jared M.</au><au>Grant, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?</atitle><jtitle>Current HIV/AIDS reports</jtitle><stitle>Curr HIV/AIDS Rep</stitle><addtitle>Curr HIV/AIDS Rep</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>10</volume><issue>2</issue><spage>142</spage><epage>151</epage><pages>142-151</pages><issn>1548-3568</issn><eissn>1548-3576</eissn><abstract>Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered – including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve on this effective technology.</abstract><cop>New York</cop><pub>Current Science Inc</pub><pmid>23494772</pmid><doi>10.1007/s11904-013-0157-9</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1548-3568 |
| ispartof | Current HIV/AIDS reports, 2013-06, Vol.10 (2), p.142-151 |
| issn | 1548-3568 1548-3576 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3644362 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adenine - analogs & derivatives Adenine - therapeutic use Administration, Oral Administration, Topical Anti-HIV Agents - therapeutic use Chemoprevention Female HIV Infections - drug therapy HIV Infections - prevention & control Humans Male Medication Adherence - statistics & numerical data Medicine Medicine & Public Health Organophosphonates - therapeutic use Randomized Controlled Trials as Topic Risk Reduction Behavior Section Editor Sexual Behavior - statistics & numerical data Tenofovir The Global Epidemic (Q Abdool Karim |
| title | Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T12%3A36%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Antiretrovirals%20for%20HIV%20Prevention:%20What%20Do%20We%20Know%20and%20What%20Don%E2%80%99t%20We%20Know?&rft.jtitle=Current%20HIV/AIDS%20reports&rft.au=Baeten,%20Jared%20M.&rft.date=2013-06-01&rft.volume=10&rft.issue=2&rft.spage=142&rft.epage=151&rft.pages=142-151&rft.issn=1548-3568&rft.eissn=1548-3576&rft_id=info:doi/10.1007/s11904-013-0157-9&rft_dat=%3Cproquest_pubme%3E1348503763%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1348503763&rft_id=info:pmid/23494772&rfr_iscdi=true |